135689-67-7

Upstream product

• 3249-68-1 ethyl butyroyl acetate 
• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 
• 124-42-5 acetamidine hydrochloride 
• 137860-26-5 ethyl 2-<(2'-cyanobiphenyl-4-yl)methyl>-3-oxohexanoate 

Downstream Products

• 141309-98-0 ethyl <5-<(2'-cyanobiphenyl-4-yl)methyl>-2-methyl-4-oxo-6-n-propylpyrimidin-3-yl>acetate 
• 169772-84-3 2-<5-<2'-cyanobiphenyl)methyl>-2-methyl-4-oxo-6-n-propylpyrimidin-3-yl>ethanol 
• 141310-33-0 2-<<5-<(2'-cyanobiphenyl-4-yl)methyl>-2-methyl-6-n-propylpyrimidin-4-yl>oxy>ethanol 
• 148475-98-3 8-<(2'-cyanobiphenyl-4-yl)methyl>-2-hydroxy-5-methyl-7-n-propyl-<1,2,4>-triazolo<1,5-c>pyrimidine 
• 148504-51-2 UP 269-6 
• 148474-44-6 5-<(2'-cyanobiphenyl-4-yl)methyl>-4-hydrazino-2-methyl-6-n-propylpyrimidine 
• 141310-41-0 2-<<5-<(2'-cyanobiphenyl-4-yl)methyl>-2-methyl-6-n-propylpyrimidin-4-yl>amino>ethanol 
• 141309-99-1 [5-(2'-Cyano-biphenyl-4-ylmethyl)-2-methyl-6-propyl-pyrimidin-4-ylsulfanyl]-acetic acid ethyl ester 
• 141310-48-7 ethyl 2-<<5-<2'-(cyanobiphenyl-4-yl)methyl>-2-methyl-6-n-propylpyrimidin-4-yl>oxy>acetate 

Relevant academic research and scientific papers

New process for the synthesis of UP 269-6, a 1,2,4-triazolo[1,5-c]pyrimidine derivative as a potent orally active angiotensin II antagonist

A new synthetic route to prepare the 2-hydroxy-5-methyl-7-n-propyl-8-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]m ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine (UP 269-6, Ripisartan) is described. UP 269-6 is a non-peptide angiotensin II antagonist currently in phase

Synthesis and angiotensin II receptor antagonist activity of C-linked pyrimidine derivatives

The synthesis and pharmacological activity of nonpeptide angiotensin II (Ang II) receptor antagonists are presented.These 3-N-substituted pyrimidine 4(3H)-one and 4-O,N,S-substituted pyrimidine derivatives represent a series of C-linked biphenyl tetrazole

Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists

The synthesis and pharmacological activity of new nonpeptide angiotensin II (AII) receptor antagonists are presented. These [1,2,4]-triazolo[1,5- c]pyrimidine and 1,2,4-triazolo[4,3-c]-pyrimidine derivatives represent a new class of bicyclic antagonists that produced a potent, oral antihypertensive activity in the renal artery-ligated rat model. In vitro, they displayed a high affinity for rat adrenal AII receptors and were found to be specific for the AT1 receptor subtype. A SAR study has shown the importance of the 8- [2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl for oral activity and the critical role of alkyl substituents at 5- and 7-positions. No significant differences were found between the [1,5-c] and [4,3-c] series. UP 269-6 (5- methyl-7-n-propyl-8-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-[1,2,4]- triazolo[1,5-c]pyrimidin-2(3H)-one, derivative 29) was selected as the lead compound. It was shown to be a highly potent antihypertensive derivative (decrease in mean arterial pressure of 39.6 ± 7.2 mmHg at 1 mg/kg po in renal artery-ligated rat) with a long duration of action which displayed a high affinity for adrenal AII receptors with a marked selectivity for the AT1 receptor subtype (K(i) AT1 = 24 nM; K(i) AT2 = 79 200 nM). This compound is currently undergoing extensive pharmacological and clinical development.